The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries
Advised BearingPoint, Inc. on the sale of substantially all of its assets, pursuant to a Section 363 process
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
Advised Cabot Microelectronics Corporation on its new capital management initiative, including a leveraged recapitalization via a special dividend
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
Advised the Special Committee of the Board of Directors of TNS, Inc., a leading global provider of data communications and interoperability solutions, on its sale to Siris Capital Group, a private equity firm focused on complex, control equity investments in the telecom, technology and technology-enabled business service sectors
Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV
Advised Recepta Biopharma on a capital raise
Advised Rofin-Sinar Technologies, Inc., a leading manufacturer of industrial laser sources and laser-based solutions and components, on its sale to Coherent, Inc., a leading provider of lasers and laser-based technology for scientific, commercial and industrial customers
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
Advised the Ad Hoc Group of Senior Secured Noteholders in connection with the restructuring of Goodman Networks.
Advised The Bank of New York Mellon in its role as the Indenture Trustee to selected First Lien Notes throughout Avaya’s Chapter 11 proceedings
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
Advised Wave Computing, a leading artificial intelligence solutions company developing proprietary dataflow-based architecture systems, on its successful $86mm Series E financing
Advised Ad Hoc Group of First Lien Term Loan B Lenders on the restructuring of 4L Holdings Corporation
Advised Locaweb, a pioneer in B2B tech solutions for businesses digital transformation in Brazil with 2 main pillars: BeOnline/SaaS and Commerce
Advised the Ad Hoc Group of First Lien Lenders on the Chapter 11 restructuring of Skillsoft Limited, a leading provider of e-learning and performance support solutions globally
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share